Dosage and administrationIf you would like to see the official doses, please refer to the drug facts sheet located in each package. The doses are 600 mg once or twice per day.
Side effects occur rarely, with the most common being dry mouth, nausea, pain in the upper stomach, dizziness and psychomotor agitation.
There were no reported cases of overdose.
Note: If used as a mild cognitive enhancer by otherwise healthy people, Pramiracetam should be taken over a course of 6 to 8 weeks, with main effects starting to manifest after 5 - 6 weeks of supplementation.
Country of Manufacture: Italy
Pramiracetam was discovered by scientists at Parke-Davis, USA in the late 1970s. Being chemically very similar to Choline, Pramiracetam causes formation of nitric oxide - a powerful vasodilator, which is crucial for short-term memory. It also affects neuropeptide mediation, as a result improving memory and learning processes. One interesting thing about pramiracetam is that it has higher potency than piracetam: the most common dose is only 600 Mg - 4 times smaller than that of Piracetam. Another interesting fact is that it has a very late onset of first effects: in most cases they should not be expected until 5-6 weeks into the course. In some cases Pramiracetam can also be used as an antidepressant.
Pramistar is usually prescribed to older patients and adults for the following indications:
- Symptomatic treatment of various memory disorders
- Treatment-resistant depressions
- Psychoorganic syndrome with asthenia.
- Emotional lability
- Other conditions characterised by lowered motivation
If used as a mild cognitive enhancer by otherwise healthy people Pramiracetam should be normally taken for a course of 6 to 8 weeks, with main effects starting to manifest after 5-6 weeks of supplementation. Some individuals report sudden but strong effects such as photographic memory after they take place.
One pack of Pramistar ® contains 20 pills, each containing 600 Mg of the active ingredient, which is sufficient for an average of 10 days of supplementation.
Country of Manufacture: Italy
- Butler et al (1984) Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam https://www.ncbi.nlm.nih.gov/pubmed/6716406
- Chang et al (1985) Pharmacokinetics of oral pramiracetam in normal volunteers https://www.ncbi.nlm.nih.gov/pubmed/4008675
- C Murray, H Fibiger (1986) The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task https://www.ncbi.nlm.nih.gov/pubmed/3088666
- Claus et al (1991) Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam https://www.ncbi.nlm.nih.gov/pubmed/2011259
- McLean et al (1991) Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia https://www.ncbi.nlm.nih.gov/pubmed/1786500
- Auteri et al (1992) Pharmacokinetics of pramiracetam in healthy volunteers after oral administration https://www.ncbi.nlm.nih.gov/pubmed/1473879
- F Talih, J Ajaltouni (2015) Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756795/